P3 Prostate Cancer Forum: 2024
Session 2 - Decoding mHSPC: Unravelling the complexities

In session 2, our experts share their insights on optimising treatment in mHSPC, delving specifically into triple therapy: data, case studies and holistic patient management.
This session is split into three parts:
Optimising triple therapy in mHSPC – Professor Alison Birtle
Exploring real-world use of triple therapy: A case based discussion – Dr Doraid Alrifai, Professor Andrew Protheroe
Adverse Event Management: Focusing on Quality of Life and Multi-Disciplinary case – Dr Mark Prentice and Fayiza Habeeb
Optimising triple therapy in mHSPC
Professor Alison Birtle
Download the summary below for the key takeaways from this meeting.
In session 3, we gained insights into nmCRPC patients in the UK, and discussed how the treatment paradigm is shifting in this patient group, as next-generation imaging becomes increasingly available and primary treatment choices are changing.
PP-NUB-GB-2016, January 2025